Trial Profile
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15211 in Obese Subjects With NAFLD
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Aug 2020
Price :
$35
*
At a glance
- Drugs Efocipegtrutide (Primary)
- Indications Non-alcoholic fatty liver disease; Obesity
- Focus Adverse reactions
- Sponsors Hanmi Pharmaceutical
- 06 Aug 2020 Status changed from recruiting to completed.
- 23 Nov 2018 New trial record